March 22, 2024 11:22 AM EDTUpdated 12:40 PM
News Briefing

In­tel­lia ex­its he­mo­phil­ia B pact with Re­gen­eron; Sang­amo tar­gets $24M raise

ENDPOINTS

Plus, news about OKYO Phar­ma:

In­tel­lia de­parts Re­gen­eron deal: The CRISPR biotech dis­closed Fri­day that it had opt­ed out of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times